Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)
Status:
Active, not recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This protocol for Varlitinib is developed for the treatment of Gastric Cancer. Varlitinib
(also known as ASLAN001) is a small-molecule, adenosine triphosphate competitive inhibitor of
the tyrosine kinases - epidermal growth factor receptor (EGFR), human epidermal growth factor
receptor (HER)2, and HER4. Varlitinib may be beneficial to subjects with cancer by
simultaneous inhibition of these receptors. The purpose of this study is to determine the
safety and efficacy of Varlitinib in combination with mFOLFOX6 for the treatment of Gastric
Cancer. Treatment groups are Varlitinib+mFOLFOX6 and Placebo+mFOLFOX6.